IL1B and COVID-19: Although the specific mechanisms and pathways are not clear, the use of BTK inhibitors (BTKis) for the treatment of COVID‐19 results in a significant reduction of proinflammatory factors, such as IL‐6, IL‐1, TNFα, as well as relief of excessive inflammatory responses, ARDS, and thrombosis in the lung (reviewed in Refs.